SCIG Hizentra denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for scig hizentra are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Hizentra on Medical-Necessity Grounds

Aetna may issue a medical-necessity denial for Hizentra (immune globulin 20%, subcutaneous) when the clinical record does not clearly document that the patient meets the diagnostic and severity criteria Aetna requires for subcutaneous immunoglobulin (SCIG) replacement. Common triggers include an incomplete record of the underlying immunodeficiency diagnosis, absence of documented infection history or functional immune testing, or a failure to show that the prescribing setting and route (subcutaneous home infusion) are medically appropriate for this patient.

## Why This Denial Is Appealable

Hizentra is FDA-approved for its indicated conditions, and immunoglobulin replacement therapy is the established standard of care for diagnosed primary immunodeficiency and certain neuromuscular conditions. Aetna's medical-necessity criteria must align with that evidence base. If your chart supports the diagnosis and clinical need, a denial based on medical necessity is highly challengeable with the right documentation.

## Federal Appeal Framework

• Internal appeal (Level 1): Submit within your plan's deadline (typically 180 days from denial notice). Aetna must respond within 30 days for non-urgent requests.
• External review (ACA §2719 / ERISA §503): If the internal appeal is upheld, you have the right to an Independent Review Organization (IRO) review. Request this within 4 months of the final internal denial. The IRO decision is binding on Aetna.
• Expedited review: If your condition is urgent, request expedited internal and external review simultaneously — Aetna must respond within 72 hours.

## Documentation to Gather

1. Diagnosis confirmation — specialist records establishing the specific immunodeficiency or qualifying condition, including immune function testing results and clinical interpretation. 2. Infection/clinical history — dated records of recurrent infections, hospitalizations, or clinical deterioration that demonstrate severity and ongoing need. 3. Prior treatment history — documentation of any prior immunoglobulin therapy (route, setting, duration, tolerance, outcomes). 4. Route justification — a prescriber letter explaining why subcutaneous home administration is medically appropriate (e.g., tolerability, venous access, patient safety, self-administration capability). 5. Prescriber medical-necessity letter — a detailed letter from the treating immunologist or neurologist stating the diagnosis, clinical rationale, and why Hizentra specifically meets the patient's needs.

## Criteria-Mapping Strategy

Obtain a copy of Aetna's current published medical policy for immunoglobulin therapy. List every stated coverage requirement. For each requirement, cite the exact page and date of the chart note, test result, or specialist record that satisfies it. This one-to-one mapping is the most persuasive structure for both internal reviewers and an IRO. Confirm that the dose and frequency requested match the FDA-approved prescribing information for the patient's indication.